levofloxacin has been researched along with bromocriptine in 4 studies
Studies (levofloxacin) | Trials (levofloxacin) | Recent Studies (post-2010) (levofloxacin) | Studies (bromocriptine) | Trials (bromocriptine) | Recent Studies (post-2010) (bromocriptine) |
---|---|---|---|---|---|
4,346 | 581 | 2,209 | 7,121 | 727 | 499 |
Protein | Taxonomy | levofloxacin (IC50) | bromocriptine (IC50) |
---|---|---|---|
5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.532 | |
Beta-1 adrenergic receptor | Homo sapiens (human) | 2.4 | |
Cytochrome P450 3A4 | Homo sapiens (human) | 2.4996 | |
Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.015 | |
D(2) dopamine receptor | Homo sapiens (human) | 0.0016 | |
Androgen receptor | Rattus norvegicus (Norway rat) | 2.281 | |
Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.035 | |
Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.52 | |
D | Rattus norvegicus (Norway rat) | 0.0279 | |
D(3) dopamine receptor | Rattus norvegicus (Norway rat) | 0.0279 | |
5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.0056 | |
Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.514 | |
D(1A) dopamine receptor | Homo sapiens (human) | 2.889 | |
Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | 0.514 | |
Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.514 | |
Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.03 | |
D(1B) dopamine receptor | Rattus norvegicus (Norway rat) | 0.0279 | |
5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.036 | |
5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.532 | |
5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.0056 | |
D(4) dopamine receptor | Rattus norvegicus (Norway rat) | 0.0279 | |
D(3) dopamine receptor | Homo sapiens (human) | 0.0006 | |
5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.0083 | |
5-hydroxytryptamine receptor 6 | Homo sapiens (human) | 0.022 | |
D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.0279 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (50.00) | 29.6817 |
2010's | 2 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for levofloxacin and bromocriptine
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 other study(ies) available for levofloxacin and bromocriptine
Article | Year |
---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |